UPDATE | September 18, 2020

Samsung Biologics Inks Service Pact with Panolos Bioscience

  • MAIL
Plant3 Samsung Biologics

Samsung Biologics has entered into a service agreement with Panolos Bioscience to develop PB101, an Fc-fusion protein intended to treat solid tumors. Samsung Biologics will provide a full scope of development services from cell line development, process development, to non-clinical and clinical material manufacturing.


All rights are reserved by the media that published this article. 
Plant3 Samsung Biologics

Samsung Biologics has entered into a service agreement with Panolos Bioscience to develop PB101, an Fc-fusion protein intended to treat solid tumors. Samsung Biologics will provide a full scope of development services from cell line development, process development, to non-clinical and clinical material manufacturing.


All rights are reserved by the media that published this article. 
  • CDO
  • CGMP
  • ADC
  • Bio Campus
  • IR
  • CMO

Share article

  • MAIL

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Interests
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please fill out the form
to view the full content

Please sign up to view the post..
* Required
Privacy Policy required